ArticleJournal of translational medicine2025
Spatial features of tumor-infiltrating lymphocytes in primary lesions of lung adenocarcinoma predict lymph node metastasis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SIRT2 is associated with prognosis, ferroptosis susceptibility, and immune infiltration in lung adenocarcinoma.Frontiers in oncology · 2026Article
- AI-driven spatial analysis of tumor-infiltrating lymphocytes predicts chemo-immunotherapy response in triple-negative breast cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLymph node metastasis (LNM) is critical for staging, prognosis, and treatment decisions in lung adenocarcinoma (LUAD). While tumor-infiltrating lymphocytes (TILs) have demonstrated prognostic value, their role in LNM risk remains uninvestigated. This study evaluates the relationship between TIL features from primary tumor whole slide images (WSIs) and LNM in LUAD.
methodsTILScout was utilized to derive patch-level TIL scores and generate global TIL maps from primary tumor WSIs. Hot spot analysis and deep learning-based feature extraction followed by K-means clustering were applied to identify and characterize spatial TIL clusters (sTILCs) from the global TIL maps. Random forest models incorporating clinical/pathological data with (M1) and without (M2) TIL features (TIL scores and sTILCs) were developed on a training cohort (N = 312) to predict LNM, and performance was compared across validation (N = 78) and independent test cohorts (N = 148).
resultsTwo sTILC types ("TIL-cold" cluster [sTILC1] and "TIL-hot" cluster [sTILC2]) were identified. Model M1 significantly improved LNM prediction over M2, with AUCs increasing from 0.63 to 0.78 (Z = 5.366, P < 0.001) and from 0.61 to 0.72 (Z = 1.999, P = 0.046) in the training and validation cohorts, and from 0.69 to 0.80 (Z = 3.030, P = 0.002) in the test cohort. Decision curve analysis indicated that M1 provided greater net benefit across a broad spectrum of threshold probabilities. Importantly, patients with lower TIL scores and/or classified as sTILC1 consistently had an increased risk of LNM.
conclusionsSpatial TIL features in primary tumors are linked to LNM in LUAD, thereby enabling the identification of high-risk patients and guiding personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.